Marco Taglietti, Scynexis CEO
Scynexis will pit a new class of antifungals against yeast infections — and it won't come cheap
The FDA ushered in a new class of triterpenoid antifungals this week, giving Scynexis the OK for its oral ibrexafungerp — a non-azole treatment the company …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
